Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.

Shaw KL, Garabedian E, Mishra S, Barman P, Davila A, Carbonaro D, Shupien S, Silvin C, Geiger S, Nowicki B, Smogorzewska EM, Brown B, Wang X, de Oliveira S, Choi Y, Ikeda A, Terrazas D, Fu PY, Yu A, Fernandez BC, Cooper AR, Engel B, Podsakoff G, Balamurugan A, Anderson S, Muul L, Jagadeesh GJ, Kapoor N, Tse J, Moore TB, Purdy K, Rishi R, Mohan K, Skoda-Smith S, Buchbinder D, Abraham RS, Scharenberg A, Yang OO, Cornetta K, Gjertson D, Hershfield M, Sokolic R, Candotti F, Kohn DB.

J Clin Invest. 2017 May 1;127(5):1689-1699. doi: 10.1172/JCI90367. Epub 2017 Mar 27.

2.

Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.

Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C, Schurman SH, Garabedian E, Kesserwan C, Jagadeesh GJ, Fu PY, Gschweng E, Cooper A, Tisdale JF, Weinberg KI, Crooks GM, Kapoor N, Shah A, Abdel-Azim H, Yu XJ, Smogorzewska M, Wayne AS, Rosenblatt HM, Davis CM, Hanson C, Rishi RG, Wang X, Gjertson D, Yang OO, Balamurugan A, Bauer G, Ireland JA, Engel BC, Podsakoff GM, Hershfield MS, Blaese RM, Parkman R, Kohn DB.

Blood. 2012 Nov 1;120(18):3635-46. doi: 10.1182/blood-2012-02-400937. Epub 2012 Sep 11.

3.

Measurement of proliferative responses of cultured lymphocytes.

Muul LM, Heine G, Silvin C, James SP, Candotti F, Radbruch A, Worm M.

Curr Protoc Immunol. 2011 Aug;Chapter 7:Unit7.10. doi: 10.1002/0471142735.im0710s94.

PMID:
21809319
4.

Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants.

Davis BR, Yan Q, Bui JH, Felix K, Moratto D, Muul LM, Prokopishyn NL, Blaese RM, Candotti F.

Clin Immunol. 2010 Apr;135(1):72-83. doi: 10.1016/j.clim.2009.12.011. Epub 2010 Feb 2.

PMID:
20123155
5.

Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondii.

Watford WT, Hissong BD, Durant LR, Yamane H, Muul LM, Kanno Y, Tato CM, Ramos HL, Berger AE, Mielke L, Pesu M, Solomon B, Frucht DM, Paul WE, Sher A, Jankovic D, Tsichlis PN, O'Shea JJ.

J Exp Med. 2008 Nov 24;205(12):2803-12. doi: 10.1084/jem.20081461. Epub 2008 Nov 10.

6.

Measurement of proliferative responses of cultured lymphocytes.

Muul LM, Silvin C, James SP, Candotti F.

Curr Protoc Immunol. 2008 Aug;Chapter 7:Unit 7.10.1-7.10.24. doi: 10.1002/0471142735.im0710s82.

PMID:
18729064
7.

Unprecedented diversity of genotypic revertants in lymphocytes of a patient with Wiskott-Aldrich syndrome.

Davis BR, Dicola MJ, Prokopishyn NL, Rosenberg JB, Moratto D, Muul LM, Candotti F, Michael Blaese R.

Blood. 2008 May 15;111(10):5064-7. doi: 10.1182/blood-2007-06-095299. Epub 2008 Mar 10.

8.

Immune responses to gene-modified T cells.

Muul LM, Candotti F.

Curr Gene Ther. 2007 Oct;7(5):361-8. Review.

PMID:
17979682
9.

Distinct regulation of interleukin-17 in human T helper lymphocytes.

Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ.

Arthritis Rheum. 2007 Sep;56(9):2936-46.

10.

Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans.

Sakamoto N, Tsuji K, Muul LM, Lawler AM, Petricoin EF, Candotti F, Metcalf JA, Tavel JA, Lane HC, Urba WJ, Fox BA, Varki A, Lunney JK, Rosenberg AS.

Blood. 2007 Jul 15;110(2):501-8. Epub 2007 Mar 29.

11.

Proprotein convertase furin is preferentially expressed in T helper 1 cells and regulates interferon gamma.

Pesu M, Muul L, Kanno Y, O'Shea JJ.

Blood. 2006 Aug 1;108(3):983-5. Epub 2006 Apr 20.

12.

Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals.

Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC.

Hum Gene Ther. 2005 Sep;16(9):1065-74.

PMID:
16149905
13.

Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4.

Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ.

Immunol Rev. 2004 Dec;202:139-56. Review.

PMID:
15546391
14.

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Alleyne M, Brown M, Bernstein W, Schurman SH, Fleisher TA, Leitman SF, Dunbar CE, Blaese RM, Candotti F.

Blood. 2003 Apr 1;101(7):2563-9. Epub 2002 Nov 27.

15.

Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy.

Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM.

Hum Gene Ther. 2002 Sep 1;13(13):1605-10.

PMID:
12228015
16.

Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone.

Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T.

Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8932-7.

17.

Flow cytometry analysis of adenosine deaminase (ADA) expression: a simple and reliable tool for the assessment of ADA-deficient patients before and after gene therapy.

Otsu M, Hershfield MS, Tuschong LM, Muul LM, Onodera M, Ariga T, Sakiyama Y, Candotti F.

Hum Gene Ther. 2002 Feb 10;13(3):425-32.

PMID:
11860709
18.

Unexpected and variable phenotypes in a family with JAK3 deficiency.

Frucht DM, Gadina M, Jagadeesh GJ, Aksentijevich I, Takada K, Bleesing JJ, Nelson J, Muul LM, Perham G, Morgan G, Gerritsen EJ, Schumacher RF, Mella P, Veys PA, Fleisher TA, Kaminski ER, Notarangelo LD, O'Shea JJ, Candotti F.

Genes Immun. 2001 Dec;2(8):422-32.

19.

Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model.

Heim DA, Hanazono Y, Giri N, Wu T, Childs R, Sellers SE, Muul L, Agricola BA, Metzger ME, Donahue RE, Tisdale JF, Dunbar CE.

Mol Ther. 2000 Jun;1(6):533-44.

20.

Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults.

Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, Leitman SF, Klein HG, Mullen CA, Metcalf JA, Baseler M, Falloon J, Davey RT Jr, Kovacs JA, Polis MA, Masur H, Blaese RM, Lane HC.

Nat Med. 1998 Jul;4(7):852-6.

PMID:
9662381
21.

T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates.

Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, Chan R, Burotto F, Annett G, Nolta JA, Crooks G, Kapoor N, Elder M, Wara D, Bowen T, Madsen E, Snyder FF, Bastian J, Muul L, Blaese RM, Weinberg K, Parkman R.

Nat Med. 1998 Jul;4(7):775-80.

22.

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH.

Nat Med. 1997 Dec;3(12):1354-61.

PMID:
9396605
23.

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF.

Science. 1995 Oct 20;270(5235):475-80.

PMID:
7570001
24.

High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.

Bunnell BA, Muul LM, Donahue RE, Blaese RM, Morgan RA.

Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7739-43.

25.

The role of mucosal immunity in development of an acquired immunodeficiency syndrome (AIDS) vaccine: workshop summary.

Muul LM, Glass MJ, Wescott SL, Burkhardt AL, Koff WC, Strober WG.

Reg Immunol. 1989 May-Jun;2(3):188-92. Review.

PMID:
2701579
26.

Morphology of interleukin-2-stimulated human peripheral blood mononuclear effector cells killing glioma-derived tumor cells in vitro.

Hook GR, Greenwood MA, Barba D, Ikejiri B, Chen SN, Oldfield EH, Weber RJ, Muul LM.

J Natl Cancer Inst. 1988 Apr 6;80(3):171-7.

PMID:
3258038
27.

Technical aspects of lymphokine-activated killer cell production.

Carter CS, Leitman SF, Cullis H, Muul LM, Nason-Burchenal K, Rosenberg SA, Klein HG.

J Clin Apher. 1988;4(2-3):113-7.

PMID:
3397372
28.
29.

Studies of serum-free culture medium in the generation of lymphokine activated killer cells.

Muul LM, Nason-Burchenal K, Hyatt C, Schwarz S, Slavin D, Director EP, Rosenberg SA.

J Immunol Methods. 1987 Dec 24;105(2):183-92.

PMID:
3693906
30.

Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

Topalian SL, Muul LM, Solomon D, Rosenberg SA.

J Immunol Methods. 1987 Aug 24;102(1):127-41.

PMID:
3305708
31.

Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy.

Muul LM, Nason-Burchenal K, Carter CS, Cullis H, Slavin D, Hyatt C, Director EP, Leitman SF, Klein HG, Rosenberg SA.

J Immunol Methods. 1987 Aug 3;101(2):171-81.

PMID:
3611795
32.

Use of a continuous-flow cell separator in density gradient isolation of lymphocytes.

Carter CS, Leitman SF, Cullis H, Muul LM, Nason-Burchenal K, Rosenberg SA, Klein HG.

Transfusion. 1987 Jul-Aug;27(4):362-5.

PMID:
3603668
33.

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.

N Engl J Med. 1987 Apr 9;316(15):889-97.

PMID:
3493432
34.

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

Muul LM, Spiess PJ, Director EP, Rosenberg SA.

J Immunol. 1987 Feb 1;138(3):989-95.

PMID:
3100623
35.

Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell.

Skibber JM, Lotze MT, Muul LM, Uppenkamp IK, Ross W, Rosenberg SA.

Nat Immun Cell Growth Regul. 1987;6(6):291-305.

PMID:
2896297
36.

Extracorporeal cellular immunotherapy.

Leonard EF, Ikebe K, Lauffenburger D, Muul L.

ASAIO Trans. 1986 Oct-Dec;32(2):633-8. No abstract available.

PMID:
3492215
37.

A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C.

Surgery. 1986 Aug;100(2):262-72.

PMID:
3526604
38.

Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy.

Muul LM, Director EP, Hyatt CL, Rosenberg SA.

J Immunol Methods. 1986 Apr 17;88(2):265-75.

PMID:
3485692
39.

Ultrastructural features of the lymphocyte-stimulated halos produced by human glioma-derived cells in vitro.

Oberc-Greenwood MA, Muul LM, Gately MK, Kornblith PL, Smith BH.

J Neurooncol. 1986;3(4):387-96.

PMID:
2420943
40.

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al.

N Engl J Med. 1985 Dec 5;313(23):1485-92.

PMID:
3903508
42.

In vitro studies on the cell-mediated immune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack.

Gately CL, Muul LM, Greenwood MA, Papazoglou S, Dick SJ, Kornblith PL, Smith BH, Gately MK.

J Immunol. 1984 Dec;133(6):3387-95.

PMID:
6238097
44.

Polyclonal activation of the murine immune system by an antibody to IgD. III. Ontogeny.

Muul LM, Mond JJ, Finkelman FD.

Eur J Immunol. 1983 Nov;13(11):900-5.

PMID:
6605861
45.
46.
47.

Stimulation of the murine immune system by anti-IgD antibodies: a polyclonal model of B-lymphocyte activation by a thymus dependent antigen.

Finkelman FD, Muul LM, Yaffe L, Scher I, Mond JJ, Kessler SW, Ryan J, Kung JT, Metcalf ES.

Ann N Y Acad Sci. 1982;399:316-28. No abstract available.

PMID:
6984615
48.

Activation of leukemic pro-suppressor cells to become suppressor-effector cells. Influence of cooperating normal T cells.

Broder S, Uchiyama T, Muul LM, Goldman C, Sharrow S, Poplack DG, Waldmann TA.

N Engl J Med. 1981 Jun 4;304(23):1382-7.

PMID:
6453293
49.

Abnormalities of immunoregulatory cells in immunodeficiency disease and cancer.

Broder S, Muul L, Megson M, Waldmann TA.

Prog Clin Biol Res. 1981;58:93-120. Review. No abstract available.

PMID:
6455670
50.

Neoplasms of immunoregulatory T cells in clinical investigation.

Broder S, Muul L, Marshall S, Waldmann TA.

J Invest Dermatol. 1980 May;74(5):267-71.

Supplemental Content

Support Center